52 results about "Advanced Solid Tumor" patented technology

Provided are methods for clinical treatment of malignant tumors (e.g., advanced solid tumors) using a combination of an anti-LAG-3 antibody, an anti-PD-1 antibody, and an immunotherapeutic agent.

Provided are methods for clinical treatment of tumors (e.g., advanced solid tumors) using an anti-LAG-3 antibody in combination with an anti-PD-1 antibody.

The present invention pertains to the technical field of drug application and particularly relates to clinical use of a KRAS G12D inhibitor. The inhibitor can be clinically used to effectively treat patients with advanced solid tumors carrying the KRAS G12D mutation and can produce beneficial effects.

Provided herein are methods of treating advanced solid tumors in a subject in need thereof, for example, when the subject has advanced head and neck squamous cell carcinoma, colorectal cancer, non-small cell lung cancer, and bladder transitional cell carcinoma. Also provided herein are methods of treating leukemia (e.g., acute myelogenous leukemia) in a subject in need thereof.

The invention belongs to the technical field of tumor resistance, and particularly relates to a cabazitaxel albumin composition and application thereof. The cabazitaxel albumin composition comprises cabazitaxel and human serum albumin, and does not contain a surfactant; the solution is a clear solution in a liquid state; the present invention relates to a Cabazitaxel injection for use in the treatment of a cancer patient by infusion administration, the dosage of Cabazitaxel infused to said patient being about 10-40 mg / m2, preferably 20 mg / m2 or 25 mg / m2, optionally in combination with a corticoid, such as prednisone, optionally repeatedly administered to said patient at a new cycle per 3 weeks, having lower adverse effects than originally developed Cabazitaxel injections, and more particularly to a Cabazitaxel injection for use in the treatment of cancer patients. And a higher disease control rate is achieved for patients with advanced solid tumors.

This invention relates to the application of mitochondrial extracts in reversing drug resistance in solid tumors. By combining mitochondrial extracts with chemotherapeutic drugs, the resistance of chemotherapeutic-resistant solid tumors to these drugs can be reversed. Compared to using mitochondrial extracts and chemotherapeutic drugs alone, this method effectively enhances drug efficacy, thereby overcoming chemotherapeutic resistance in solid tumors. This invention, through intervention with mitochondrial extracts in different chemotherapeutic-resistant solid tumor cell lines, has verified that the combined use of mitochondrial transplantation and chemotherapeutic drugs can reverse chemotherapeutic resistance, thereby improving the efficacy of chemotherapy and opening up the possibility of continued treatment for patients with advanced solid tumors who are resistant to chemotherapeutic drugs.

This article provides information on multi-chain chimeric peptides and their use in the treatment of unresectable, advanced, recurrent and / or metastatic solid tumors or unresectable, advanced, recurrent and / or metastatic solid cancers.

The present invention concerns an A3 adenosine receptor (A3AR) ligand for use in the treatment of an advanced solid tumor, e.g., hepatocellular carcinoma (HCC) in a mammalian subject.

Provided herein are methods of treating advanced solid tumors using a compound of Formula (I) or a pharmaceutically acceptable form thereof, including methods of treating advanced solid tumors using a compound of Formula (I) or a pharmaceutically acceptable form thereof in combination with a VEGFR inhibitor.

This disclosure relates to methods and compositions for treating cancer including advanced solid tumor, a metastatic solid tumor or lymphoma using an inducible IL-12 prodrug.

The invention relates to the technical field of medical health, in particular to an intelligent evaluation and intervention system for muscle quality of a patient with advanced solid tumors. The multi-dimensional dynamic evaluation unit is used for forming the extracted somatic cell mass, the score of the anorexia-cachexia syndrome, the standardized skeletal muscle index and the average muscle radiation attenuation value into multi-dimensional feature data, and the multi-dimensional dynamic evaluation unit is used for evaluating the quality of the somatic cells on the basis of the multi-dimensional feature data and fusing tumor treatment scheme data. Generating a multi-dimensional muscle health index and a malignant fluid risk probability through a decision tree model, and dividing patients into different risk levels; and the intervention strategy generation unit is used for outputting a comprehensive intervention scheme based on the multi-dimensional muscle health index and the malignant fluid risk probability in combination with the real-time tolerance data and the risk level of the patient. According to the system, the L3 level skeletal muscle index and the muscle radiation attenuation value can be extracted more accurately and stably, manual annotation and manual variation are reduced, and the reliability of image quantification is improved.

The present disclosure relates to novel radiation-triggered controlled release drug compositions, and methods to make and use the radiation-triggered controlled release drug compositions. The radiation-triggered controlled drug release nanoparticle formulations may be used to achieve maximum bioavailability and minimum adverse effects of the chemo drugs in chemo radio combination therapy treatment of locally advanced solid tumors.

Provided herein are methods for treating cancer in an individual comprising administering an oncolytic virus in combination with a PD-1 antibody. The provided methods trigger an abscopal response in distant tumors, facilitating the systemic activation of the immune system to identify and target untreated tumor sites. By harnessing the dual mechanisms of oncolytic viruses and immune checkpoint inhibition, the methods provided herein enhance overall treatment efficacy, offering a novel approach to the treatment of various types of malignancies.

Methods for treating solid tumors with anti-PD-L1 and anti-CTLA-4 antibodies concurrently with chemoradiotherapy (cCRT) are disclosed.

Provided herein are multi-chain chimeric polypeptides and use thereof in the treatment of an unresectable, advanced, recurrent, and / or metastatic solid tumor or an unresectable, advanced, recurrent, and / or metastatic solid cancer.

This disclosure relates to methods and compositions for treating cancer, including advanced solid tumors, metastatic solid tumors, or lymphoma, using an inducible IL-12 prodrug. This disclosure relates to compositions and methods for treating cancer using an inducible IL-12 prodrug. This inducible IL-12 prodrug contains attenuated IL-12 and has a longer half-life compared to naturally occurring IL-12. Optionally, IL-12 may be mutein. IL-12 mutein may be aglycosylated or partially aglycosylated.

The present invention belongs to the technical field of anti-tumor medicine. Provided are a cabazitaxel albumin composition and the use thereof. The cabazitaxel albumin composition comprises cabazitaxel and a human serum albumin, and does not contain a surfactant. The cabazitaxel albumin composition is a clear solution in a liquid state, which is administered by means of infusion for the treatment of a cancer patient. The dosage of the cabazitaxel infused to the patient is about 10-40 mg / m 2, preferably 20 mg / m 2 or 25 mg / m 2. The cabazitaxel albumin composition is optionally used in combination with a corticosteroid (such as prednisone), and is optionally administered repeatedly to the patient every 3 weeks as a new cycle. The cabazitaxel albumin composition has fewer adverse effects and a higher disease control rate for a patient with advanced solid tumors compared to the originally developed cabazitaxel injection.

CD73 catalyzes the formation of extracellular adenosine, which promotes an immunosuppressive tumor environment. CD73 is overexpressed in stromal cells and various types of tumor cells. A method of treating a solid tumor is provided. In particular, a method is provided for treating solid tumors, such as advanced solid tumors, by using an anti-CD73 antibody or antigen-binding fragment thereof.

The present invention provides a use of a paclitaxel cationic liposome in preparation of a drug for treating advanced solid tumors, a use of the paclitaxel cationic liposome and a system therapeutic drug in preparation of a drug for treating advanced solid tumors, and a method for treating advanced solid tumors. A therapeutically effective amount of paclitaxel cationic liposome is administered to patients with advanced solid tumors, or a therapeutically effective amount of paclitaxel cationic liposome and system therapeutic drug is administered to patients with advanced solid tumors.

The invention relates to a pharmaceutical composition and application thereof in preparation of drugs for treating chemotherapeutic drug-resistant solid tumors, the pharmaceutical composition comprises a targeted CDK9 degradation agent and platinum chemotherapeutic drugs, and the targeted CDK9 degradation agent is a compound shown in a general formula (I), a tautomer, a diastereomer, a racemate and a pharmaceutically acceptable salt thereof. The pharmaceutical composition provided by the invention has drug resistance to some platinum chemotherapeutic drugs, and the drug resistance mechanism of solid tumor cells or local advanced solid tumor cells is not clear; particularly, the compound has the effects of remarkably inhibiting the clone formation capability, effectively promoting cell apoptosis and reversing the drug resistance of solid tumors on esophageal squamous carcinoma cells resistant to platinum chemotherapeutic drugs.

Provided herein are methods of treating advanced solid tumors in a subject in need thereof, for example, when the subject has advanced squamous cell carcinoma of the head and neck, colorectal cancer, non-small cell lung cancer, and transitional cell carcinoma of the bladder. Also provided herein are methods of treating blood cancers, such as acute myeloid leukemia, in a subject in need thereof.

The present disclosure provides methods for treating cancer, such as an advanced solid tumor, in a subject in need thereof by administering to the subject an effective first dose of an IL-12 albumin binding domain (ABD) fusion protein, and every three or four weeks after administration of the first dose, an effective second dose of the IL-12 ABD fusion protein, wherein the second dose is greater than the first dose.

Methods for using anti-B7-H4 antibody-drug conjugates for the treatment of cancers, such as, e.g., B7-H4-associated solid tumors and breast cancer (e.g, ovarian cancer, primary peritoneal cancer, fallopian tube cancer, breast cancer, endometrial carcinoma, lung cancer, cholangiocarcinoma, gallbladder carcinoma, and head and neck carcinoma), are provided.

PI3Kδ implicates hematologic cancers and solid tumors. Alternative splicing is a post-transcriptional process for acquiring proteomic diversity in eukaryotic cells. Emerging evidence highlights the involvement of aberrant mRNA splicing in cancer development / progression. PI3Kδ-L and PI3Kδ-S are overexpressed in advanced solid tumors, such as prostate, breast, colon, lung and pancreatic cancers. Differential PI3Kδ and PI3Kδ-S expression profiles were identified in a panel of solid tumor cells. PI3Kδ inhibitor Idelalisib and SRPK1 / 2 inhibitor SRPIN340 were employed to assess their efficacies on inhibiting the PI3Kδ-expressing solid tumors. Idelalisib effectively inhibits PI3Kδ-L and its downstream signaling. Idelalisib fails to inhibit PI3Kδ-S activity and its downstream signaling. SRPIN340 reverses the aberrant mRNA splicing, thereby inhibiting the downstream AKT / mTOR signaling. In vitro functional assays further demonstrate that a combination of Idelalisib and SRPIN340 achieve a synergistic drug effect, with drastically reduced cell viabilities / growths of tumor spheroids, in inhibiting the advanced tumor cells.

The present application relates, inter alia, to improved methods of treating solid tumors, including, but not limited to, non-small cell lung cancer ('NSCLC') tumors, gastroesophageal adenocarcinoma ('GEA') tumors, colorectal cancer ('CRC') tumors, and advanced solid tumors of MET gene amplification, using anti-c-Met antibody drug conjugates ('anti-c-Met ADC'). In particular embodiments, the anti-c-Met ADC consists of a c-Met targeting antibody, i.e., vietinirituzumab, conjugated to a potent topoisomerase 1 inhibitor (Top1i) payload.

The present application pertains to, among other things, improved methods of treating advanced solid tumors, including small cell lung cancer (“SCLC”), relapsed / refractory (R / R) SCLC, high-grade central nervous system (“CNS”) tumors (glioblastoma (“GBM”), IDH-wild-type Grade 4; oligodendroglioma, IDH-mutant, and 1p / 19q-codeleted Grade 3; astrocytoma, IDH-mutant Grade 3 or Grade 4), and high-grade neuroendocrine carcinomas / neuroendocrine tumors (“NECs / NETs”), using an anti-SEZ6 antibody drug conjugate (“anti-SEZ6 ADC”). In specific embodiments, the anti-SEZ6 ADC consists of a SEZ6-targeting antibody conjugated to a potent topoisomerase 1 inhibitor (Top1i) payload.

Advanced solid tumors remain largely incurable due to the emergence of tumor subclones. These tumor subclones, called metastatic stem cells (MetSCs), are capable of self-renewal, slow cell cycle, tumor relapse, and therapy resistance. The cell adhesion molecule L1CAM has been identified as a key target specifically on MetSCs. The presently disclosed subject matter provides antibodies or antigen-binding fragments thereof that bind to L1CAM, and methods of using such antibodies or antigen-binding fragments. The presently disclosed subject matter further provides immunoconjugates comprising anti-L1CAM antibodies or antigen-binding fragments thereof, and methods of using such immunoconjugates.

The invention provides application of a bispecific antibody to preparation of a medicine for treating cancers, in particular to application of the bispecific antibody to preparation of a medicine for treating advanced solid tumors.

Providing compounds of Formula (A) or pharmaceutically acceptable salts, solvate, stereoisomer, or isotopic variant thereof useful as PKMYT1 inhibitors, pharmaceutical compositions comprising the same, and use thereof in the manufacture of medicaments for treating PKMYT1-associated diseases or conditions such as advanced solid tumor, and etc.